Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (11923)	12/1/1997 9:07:00 AM
From: Henry Niman	Respond to of 32384

Stan, I just heard about the problem on CNBC and haven't really looked around (other than to get the PRNewswire and Dow Jones press releases).

To: squetch who wrote (11923)	12/1/1997 9:08:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Stan, The relabling news is old. The new news is GLX's decision to halt sales in Europe.

To: squetch who wrote (11923)	12/1/1997 9:16:00 AM
From: Henry Niman	Respond to of 32384

Stan, Of course not only does LGND's new retinoids (Targretin and ALRT268) synergize with the newer TZDs, they also should allow for use at lower levels. That of course is the chief benefit of basic research programs like LGND's. LGND already has 1st, 2nd, and 3rd genberation Rexinoids identified (Targretin, the first has been in patients fore 3 years. ALRT268, aka LGD1268, is slated to enter the clinic next quarter (month?)). LGND's medicinal chemists took Targretin and modified it to increase affinity and specificity. They also have LG100754 which actually eliminates the need for the TZD altogether! LGND is the leader in IR technology. Their many programs synergize with each other to come up with more effective compounds. In 10 years, investors will be amazed that these complex (at the molecular level) diseases were actually treated with only one compound (at high concentrations). WLA (and Sankyo) current problems with Rezulin are a good example of why Biotechs, with cutting edge technology, will be able to win market share from the much bigger pharmas.